SLC5A2 and hydrops fetalis: In fact, there is still no strong evidence of the theory that, in several populations with HF, including HFpEF, SGLT2 inhibitors exert a more profound impact on the clinical outcomes, surrogate image, and circulating biomarkers of adverse cardiac remodeling in female than in male patients [43].